Alnylam Pharmaceuticals (ALNY) 'Appears Oversold' on BridgeBio Pharma News - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Pharma (ALNY) Skepticism is Unwarranted, Weakness is a Major Buying Opportunity - Oppenheimer
December 28, 2021 6:02 AM ESTOppenheimer analyst Leland Gershell reiterates an "Outperform" rating and $200 price target on the shares of Alnylam Pharma (NASDAQ: ALNY), following disappointing Phase 3 data of the company's competitor - BridgeBio Pharma, Inc. (Nasdaq: BBIO). The analyst believes the... More
Why BridgeBio (BBIO) Stock Crashed 70% Today
December 27, 2021 9:21 AM ESTShares of BridgeBio Pharma (Nasdaq: BBIO) are down nearly 70% today after the company announced topline results from Month 12 (Part A) of ATTRibute-CM.
The ongoing global Phase 3 study is investigating acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).
BIO said that observes declines 6MWD at Month 12 in participants receiving acoramidis or placebo were substantially less than the >40 meter annual declines observed in... More
BridgeBio Failure a Positive for Alnylam Pharma (ALNY) - Stifel
December 27, 2021 7:52 AM ESTStifel analyst Paul Matteis said BridgeBio Pharma's (NASDAQ: BBIO) failure today of its... More
